Professor Graham Hitman, MB BS, MD, FRCP
Professor of Molecular Medicine and Diabetes
Graham Hitman graduated from University College Hospital Medical School in 1976 and did his clinical training in General Medicine and Diabetes in Kings College and associated Hospitals, St Bartholomew’s Hospital and subsequently The Royal London Hospital. He did is MD research into the genetics of diabetes with Professor David Galton at Barts and was subsequently appointed as Lecturer, Senior Lecturer and Reader at the Royal London Hospital Medical College working under Professor RD Cohen. Since 1995 he has been Professor of Molecular Medicine and Diabetes at Barts and The London School of Medicine and Dentistry. Prof Hitman was director of the Blizard Institute from October 2013 to March 2017
Current research is directed towards:
- Gene Discovery in type 2 diabetes and pharmacogenomics
- Epigenetics and its relation to foetal programing
- Prevention strategies in type 2 diabetes
Professor Graham Hitman is the co-ordinator of a FP7 grant 2012-2015 GIFTS:
‘Genomic and lifestyle predictors of foetal outcome relevant to diabetes and obesity and their relevance to prevention strategies in South Asian peoples’
Undergraduate and Postgraduate teaching
Topics for PhD supervision:
- Genomics of Diabetes
- Prevention of Diabetes
Graham Hitman’s main research interests are directed to gene discovery arising from genome-wide association scans in type 2 diabetes and the use of epigenetics to study the gene environmental interaction. In addition to GIFTS, he is also one of the principal investigators of the CARDS (Collaborative Atorvastatin Diabetes Study) trial that has influenced the development of current lipid lowering guidelines in diabetes and is a principal investigator of two pilot diabetes prevention trials one of which is an RCT of vitamin D supplementation (www.mrc-epid.cam.ac.uk/Research/Studies/VitaminD/index.html).
Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010 Jul;42(7):579-89.
Bell CG, Finer S, Lindgren CM, Wilson GA, Rakyan VK, Teschendorff AE, et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One. 2010;5(11):e14040.
Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007 May 11;316(5826):889-94.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug 21-27;364(9435):685-96.
McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999 Apr 2;97(1):133-44.
Festenstein H, Awad J, Hitman GA, Cutbush S, Groves AV, Cassell P, et al. New HLA DNA polymorphisms associated with autoimmune diseases. Nature. 1986 Jul 3-9;322(6074):64-7.
View all Graham Hitman's Research Publications at: http://www.researchpublications.qmul.ac.uk